- Home
- INZY vs MPA Comparison
INZY vs MPA Comparison
Compare INZY & MPA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INZY
- MPA
- Stock Information
- Founded
- INZY 2015
- MPA 1992
- Country
- INZY United States
- MPA United States
- Employees
- INZY N/A
- MPA N/A
- Industry
- INZY Biotechnology: Pharmaceutical Preparations
- MPA Finance Companies
- Sector
- INZY Health Care
- MPA Finance
- Exchange
- INZY Nasdaq
- MPA Nasdaq
- Market Cap
- INZY 165.1M
- MPA 159.3M
- IPO Year
- INZY 2020
- MPA N/A
- Fundamental
- Price
- INZY $2.73
- MPA $11.74
- Analyst Decision
- INZY Strong Buy
- MPA
- Analyst Count
- INZY 7
- MPA 0
- Target Price
- INZY $16.14
- MPA N/A
- AVG Volume (30 Days)
- INZY 885.2K
- MPA 25.2K
- Earning Date
- INZY 11-05-2024
- MPA 01-01-0001
- Dividend Yield
- INZY N/A
- MPA 3.83%
- EPS Growth
- INZY N/A
- MPA N/A
- EPS
- INZY N/A
- MPA N/A
- Revenue
- INZY N/A
- MPA N/A
- Revenue This Year
- INZY N/A
- MPA N/A
- Revenue Next Year
- INZY N/A
- MPA N/A
- P/E Ratio
- INZY N/A
- MPA N/A
- Revenue Growth
- INZY N/A
- MPA N/A
- 52 Week Low
- INZY $2.39
- MPA $9.87
- 52 Week High
- INZY $7.80
- MPA $12.21
- Technical
- Relative Strength Index (RSI)
- INZY 41.48
- MPA 33.06
- Support Level
- INZY $2.84
- MPA $11.78
- Resistance Level
- INZY $3.28
- MPA $12.55
- Average True Range (ATR)
- INZY 0.25
- MPA 0.14
- MACD
- INZY 0.10
- MPA -0.05
- Stochastic Oscillator
- INZY 48.84
- MPA 5.19
About INZY Inozyme Pharma Inc.
Inozyme Pharma Incclinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company is pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. The company product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 Deficiencies.
About MPA Blackrock MuniYield Pennsylvania Quality Fund
Blackrock Muniyield Pennsylvania Quality Fund is a closed-end fund with investment objective is to provide shareholders with current income exempt from U.S. federal and Pennsylvania income taxes.